Rheumatoid Arthritis News

Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data published in Rheumatology.

The FDA has approved a label update for Janssen’s golimumab to include language that treatment alongside methotrexate improves fatigue in patients with active psoriatic arthritis and moderately to severely active rheumatoid arthritis.

With proper dosing — 5 mg/kg or less per day — the risk for retinal toxicity associated with hydroxychloroquine use is less than 2% for up to 10 years, according to a joint statement from four medical societies.

The adalimumab biosimilar CT-P17 demonstrates equivalent efficacy, and comparable safety and immunogenicity, to its reference product in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

Moderate and high disease activity, as well as the use of immunosuppressants, were associated with a higher risk for COVID-related death in patients with rheumatic diseases, according to data in the Annals of the Rheumatic Diseases.

Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.

For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years.

Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.

Biosimilar use among Medicare fee-for-service beneficiaries seems to depend most on practice setting and hospital ownership status, with few patient or physician characteristics linked to usage, according to data in JAMA Network Open.

Advanced imaging and biopsy of the synovium have not led clinicians to “the promised land” in terms of guiding treatment for rheumatoid arthritis, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.